BR0209525A - Hidroxamatos de sulfona aromáticos e uso dos mesmos como inibidores de protease - Google Patents
Hidroxamatos de sulfona aromáticos e uso dos mesmos como inibidores de proteaseInfo
- Publication number
- BR0209525A BR0209525A BR0209525-4A BR0209525A BR0209525A BR 0209525 A BR0209525 A BR 0209525A BR 0209525 A BR0209525 A BR 0209525A BR 0209525 A BR0209525 A BR 0209525A
- Authority
- BR
- Brazil
- Prior art keywords
- aromatic sulfone
- protease inhibitors
- hydroxamates
- mmp
- agrecanase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
- C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ceramic Engineering (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Manufacturing & Machinery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
Abstract
"HIDROXAMATOS DE SULFONA AROMáTICOS E USO DOS MESMOS COMO INIBIDORES DE PROTEASE". A presente invenção é refere-se a hidroxamatos de sulfona aromáticos (também conhecidos como "ácidos hidroxâmicos de sulfona aromáticos") e a sais dos mesmos que, entre outros, inibem a atividade da metaloproteinase da matriz (também conhecida como "metaloprotease da matriz" ou "MMP") e/ou a atividade da agrecanase. Esta invenção também refere-se a um método de prevenção ou de tratamento que compreende administrar um tal composto ou sal em uma quantidade eficaz inibidora de MMP e/ou de agrecanase a um animal, particularmente a um mamífero que tenha (ou disposto a ter) uma condição patológica associada com atividade der MMP e/ou de agrecanase.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29037501P | 2001-05-11 | 2001-05-11 | |
PCT/US2002/015257 WO2002092588A2 (en) | 2001-05-11 | 2002-05-10 | Aromatic sulfone hydroxamates and their use as protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0209525A true BR0209525A (pt) | 2004-03-09 |
Family
ID=23115707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0209525-4A BR0209525A (pt) | 2001-05-11 | 2002-05-10 | Hidroxamatos de sulfona aromáticos e uso dos mesmos como inibidores de protease |
Country Status (26)
Country | Link |
---|---|
US (3) | US6689794B2 (pt) |
EP (1) | EP1385836A2 (pt) |
JP (1) | JP2004530691A (pt) |
KR (1) | KR20040018368A (pt) |
CN (1) | CN1764655A (pt) |
AP (1) | AP2003002908A0 (pt) |
AR (1) | AR040928A1 (pt) |
BG (1) | BG108285A (pt) |
BR (1) | BR0209525A (pt) |
CA (1) | CA2446586A1 (pt) |
CO (1) | CO5540386A2 (pt) |
CR (1) | CR7146A (pt) |
CZ (1) | CZ20032913A3 (pt) |
EA (1) | EA200301116A1 (pt) |
EC (1) | ECSP034839A (pt) |
HR (1) | HRP20030901A2 (pt) |
HU (1) | HUP0304069A2 (pt) |
IL (1) | IL158454A0 (pt) |
IS (1) | IS7003A (pt) |
MX (1) | MXPA03010326A (pt) |
NO (1) | NO20034995L (pt) |
OA (1) | OA12602A (pt) |
PL (1) | PL367487A1 (pt) |
WO (1) | WO2002092588A2 (pt) |
YU (1) | YU85403A (pt) |
ZA (1) | ZA200308525B (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999025687A1 (en) * | 1997-11-14 | 1999-05-27 | G.D. Searle & Co. | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
GB9901147D0 (en) * | 1999-01-19 | 1999-03-10 | Merck Sharp & Dohme | Therapeutic agents |
US6683093B2 (en) * | 2000-05-12 | 2004-01-27 | Pharmacia Corporation | Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
US20040024024A1 (en) * | 2001-05-11 | 2004-02-05 | Freskos John N. | Aromatic sulfone hydroxamates and their use as protease inhibitors |
US20050209278A1 (en) * | 2002-04-25 | 2005-09-22 | Mcdonald Joseph J | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
WO2003091247A2 (en) * | 2002-04-25 | 2003-11-06 | Pharmacia Corporation | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
MXPA05000171A (es) * | 2002-06-25 | 2005-04-08 | Pharmacia Corp | Acido arilsulfonilhidroxamico y derivados de amida y su uso como inhibidores de la proteasa. |
ES2537514T3 (es) | 2003-04-04 | 2015-06-09 | Incyte Corporation | Composiciones, métodos y kits relacionados con la escisión de HER-2 |
WO2004098582A2 (en) * | 2003-05-07 | 2004-11-18 | The University Court Of The University Of Aberdeen | Ketones and reduced ketones as therapeutic agents for the treatment of bone conditions |
ZA200605248B (en) * | 2003-12-15 | 2007-10-31 | Japan Tobacco Inc | Cyclopropane compounds and pharmaceutical use thereof |
WO2005061448A1 (en) * | 2003-12-24 | 2005-07-07 | Monash University | Compositions and methods for treating vascular conditions |
US20050250789A1 (en) * | 2004-04-20 | 2005-11-10 | Burns David M | Hydroxamic acid derivatives as metalloprotease inhibitors |
US7709516B2 (en) * | 2005-06-17 | 2010-05-04 | Endorecherche, Inc. | Helix 12 directed non-steroidal antiandrogens |
CA2672616A1 (en) | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
BR112015003376A8 (pt) | 2012-08-23 | 2018-01-23 | Alios Biopharma Inc | composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica |
EP3154544B1 (en) * | 2014-06-12 | 2023-08-02 | Cedars-Sinai Medical Center | Compositions and methods for treating cancers |
CN104292180A (zh) * | 2014-10-12 | 2015-01-21 | 湖南华腾制药有限公司 | 一种恶二唑衍生物的制备方法 |
CA3073810A1 (en) * | 2017-08-31 | 2019-03-07 | Ahammune Biosciences Private Limited | Thiophene-derived compounds, process for synthesis and use thereof |
KR102533605B1 (ko) * | 2018-01-10 | 2023-05-17 | 주식회사 라이조테크 | 신규한 페닐설포닐 옥사졸 유도체 및 이의 용도 |
EP4377321A1 (en) * | 2021-07-28 | 2024-06-05 | University of KwaZulu-Natal | Metallo-?-lactamase inhibitors |
CN117800921B (zh) * | 2024-02-28 | 2024-06-11 | 南京市鸿舜医药科技有限公司 | 一种咪唑烷二酮类hdac抑制剂、制备方法及应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4595700A (en) | 1984-12-21 | 1986-06-17 | G. D. Searle & Co. | Thiol based collagenase inhibitors |
US4882434A (en) | 1986-10-29 | 1989-11-21 | Takeda Chemical Industries, Ltd. | Gamma-lactonecarboxylic acid derivatives and their use as antibacterial agents or intermediates |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
JP3122161B2 (ja) | 1991-05-16 | 2001-01-09 | 武田薬品工業株式会社 | γ−ラクトン免疫抑制剤 |
EP0634998B1 (en) | 1992-04-07 | 1997-03-19 | British Biotech Pharmaceuticals Limited | Hydroxamic acid based collagenase and cytokine inhibitors |
US5376664A (en) | 1992-07-27 | 1994-12-27 | The Du Pont Merck Pharmaceutical Company | Unsymmetrical mono-3-nitro bis-naphthalimides as anticancer agents |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
GB9307956D0 (en) | 1993-04-17 | 1993-06-02 | Walls Alan J | Hydroxamic acid derivatives |
GB9320660D0 (en) | 1993-10-07 | 1993-11-24 | British Bio Technology | Inhibition of cytokine production |
GB9323165D0 (en) | 1993-11-10 | 1994-01-05 | Chiros Ltd | Compounds |
WO1995029892A1 (en) | 1994-04-28 | 1995-11-09 | The Du Pont Merck Pharmaceutical Company | Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents |
GB9416897D0 (en) | 1994-08-20 | 1994-10-12 | British Biotech Pharm | Metalloproteinase inhibitors |
PL183510B1 (pl) | 1994-10-05 | 2002-06-28 | Darwin Discovery Ltd | Związki peptydowe oraz środek farmaceutyczny |
JP2000502330A (ja) | 1995-12-08 | 2000-02-29 | アグロン・ファーマシュウティカルズ・インコーポレーテッド | メタロプロテイナーゼ阻害薬、それらを含有する薬剤組成物および薬剤としてのそれらの使用、ならびにそれらの製造に有用な方法および中間体 |
ES2183905T3 (es) | 1995-12-20 | 2003-04-01 | Hoffmann La Roche | Inhibidores de metaloproteasa de matriz. |
ATE262899T1 (de) | 1996-01-02 | 2004-04-15 | Aventis Pharma Inc | Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen |
WO1997049679A1 (fr) | 1996-06-27 | 1997-12-31 | Ono Pharmaceutical Co., Ltd. | Derives d'aryle (sulfure, oxyde sulfonique et sulfone) et medicaments les contenant en tant que principe actif |
US6013649A (en) | 1996-07-22 | 2000-01-11 | Monsanto Company | Thiol sulfone metalloprotease inhibitors |
CN1252790A (zh) | 1997-02-27 | 2000-05-10 | 美国氰胺公司 | 作为基质金属蛋白酶抑制剂的n-羟基-2-(烷基、芳基或杂芳基硫烷基、亚磺酰基或磺酰基)-3-取代的烷基、芳基或杂芳基酰胺 |
US6300514B1 (en) | 1997-06-25 | 2001-10-09 | Ono Pharmaceutical Co., Ltd. | Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient |
US6576664B1 (en) | 1997-08-18 | 2003-06-10 | Bristol-Myers Squibb Pharma Company | Inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis |
WO1999025687A1 (en) | 1997-11-14 | 1999-05-27 | G.D. Searle & Co. | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US6750228B1 (en) | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
US20010039287A1 (en) * | 1997-11-14 | 2001-11-08 | Thomas E Barta | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
IL127496A0 (en) | 1997-12-19 | 1999-10-28 | Pfizer Prod Inc | The use of MMP inhibitors for the treatment of ocular angiogenesis |
JP2002503717A (ja) | 1998-02-19 | 2002-02-05 | アメリカン・サイアナミド・カンパニー | マトリクス金属プロテイナーゼ阻害薬としてのn−ヒドロキシ−2−(アルキル、アリールまたはヘテロアリールスルファニル、スルフィニルまたはスルホニル)−3−置換−アルキル、アリールまたはヘテロアリールアミド |
PL350193A1 (en) | 1999-02-08 | 2002-11-18 | Searle & Co | Sulfamato hydroxamic acid metalloprotease inhibitor |
CA2366264A1 (en) | 1999-04-02 | 2000-10-12 | Bristol-Myers Squibb Company | Novel amide derivatives as inhibitors of matrix metalloproteinases, tnf-.alpha., and aggrecanase |
EP1081137A1 (en) | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Selective inhibitors of aggrecanase in osteoarthritis treatment |
US6683093B2 (en) | 2000-05-12 | 2004-01-27 | Pharmacia Corporation | Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
-
2002
- 2002-05-10 PL PL02367487A patent/PL367487A1/xx unknown
- 2002-05-10 EP EP02729204A patent/EP1385836A2/en not_active Withdrawn
- 2002-05-10 HU HU0304069A patent/HUP0304069A2/hu unknown
- 2002-05-10 WO PCT/US2002/015257 patent/WO2002092588A2/en not_active Application Discontinuation
- 2002-05-10 CA CA002446586A patent/CA2446586A1/en not_active Abandoned
- 2002-05-10 IL IL15845402A patent/IL158454A0/xx unknown
- 2002-05-10 CZ CZ20032913A patent/CZ20032913A3/cs unknown
- 2002-05-10 MX MXPA03010326A patent/MXPA03010326A/es unknown
- 2002-05-10 BR BR0209525-4A patent/BR0209525A/pt not_active IP Right Cessation
- 2002-05-10 KR KR10-2003-7014663A patent/KR20040018368A/ko not_active Application Discontinuation
- 2002-05-10 US US10/142,737 patent/US6689794B2/en not_active Expired - Fee Related
- 2002-05-10 YU YU85403A patent/YU85403A/sh unknown
- 2002-05-10 OA OA1200300293A patent/OA12602A/en unknown
- 2002-05-10 JP JP2002589473A patent/JP2004530691A/ja not_active Withdrawn
- 2002-05-10 AP APAP/P/2003/002908A patent/AP2003002908A0/en unknown
- 2002-05-10 AR ARP020101724A patent/AR040928A1/es unknown
- 2002-05-10 EA EA200301116A patent/EA200301116A1/ru unknown
- 2002-05-10 CN CNA02809672XA patent/CN1764655A/zh active Pending
-
2003
- 2003-01-31 ZA ZA200308525A patent/ZA200308525B/en unknown
- 2003-09-05 US US10/657,034 patent/US6890928B2/en not_active Expired - Fee Related
- 2003-10-23 BG BG108285A patent/BG108285A/bg unknown
- 2003-10-29 IS IS7003A patent/IS7003A/is unknown
- 2003-11-07 HR HR20030901A patent/HRP20030901A2/hr not_active Application Discontinuation
- 2003-11-10 NO NO20034995A patent/NO20034995L/no not_active Application Discontinuation
- 2003-11-10 CO CO03099304A patent/CO5540386A2/es not_active Application Discontinuation
- 2003-11-11 CR CR7146A patent/CR7146A/es not_active Application Discontinuation
- 2003-11-11 EC EC2003004839A patent/ECSP034839A/es unknown
-
2004
- 2004-11-17 US US10/992,483 patent/US20050101641A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2004530691A (ja) | 2004-10-07 |
HRP20030901A2 (en) | 2005-10-31 |
CR7146A (es) | 2008-02-11 |
WO2002092588A2 (en) | 2002-11-21 |
US20040110805A1 (en) | 2004-06-10 |
IL158454A0 (en) | 2004-05-12 |
NO20034995L (no) | 2003-12-16 |
CZ20032913A3 (cs) | 2004-05-12 |
WO2002092588A3 (en) | 2003-02-27 |
US6689794B2 (en) | 2004-02-10 |
BG108285A (bg) | 2004-09-30 |
MXPA03010326A (es) | 2004-07-30 |
OA12602A (en) | 2006-06-09 |
YU85403A (sh) | 2006-03-03 |
AR040928A1 (es) | 2005-04-27 |
US20050101641A1 (en) | 2005-05-12 |
CN1764655A (zh) | 2006-04-26 |
EP1385836A2 (en) | 2004-02-04 |
EA200301116A1 (ru) | 2004-06-24 |
PL367487A1 (en) | 2005-02-21 |
CA2446586A1 (en) | 2002-11-21 |
US6890928B2 (en) | 2005-05-10 |
ECSP034839A (es) | 2003-12-24 |
US20040010019A1 (en) | 2004-01-15 |
ZA200308525B (en) | 2005-02-17 |
IS7003A (is) | 2003-10-29 |
KR20040018368A (ko) | 2004-03-03 |
CO5540386A2 (es) | 2005-07-29 |
NO20034995D0 (no) | 2003-11-10 |
AP2003002908A0 (en) | 2003-12-31 |
HUP0304069A2 (hu) | 2004-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0209525A (pt) | Hidroxamatos de sulfona aromáticos e uso dos mesmos como inibidores de protease | |
BR0214450A (pt) | ácidos hidroxâmicos de sulfona aromáticos e uso dos mesmos como inibidores de protease | |
BRPI0511707A (pt) | peroxifosfatos de cálcio e sua utilização em composições dentais | |
BR0008440A (pt) | Inibidor de metaloprotease de sulfamato do ácido hidroxâmico | |
BR0213817A (pt) | Tratamento de sìndrome de resistência à insulina e diabete do tipo 2 com inibidores da pde9 | |
DK0697036T3 (da) | Sølvkorrosionsbeskyttelsesmiddel II | |
BR0304648A (pt) | Combinação de inibidores de ciclooxigenase-2 e talidomida para o tratamento de neoplasia | |
EP1446136A4 (en) | CURCUMINOID COMPOSITIONS WITH SYNERGISTIC INHIBITION OF EXPRESSION AND / OR EFFECT OF CYCLOOXYGENASE-2 | |
DE69924268D1 (de) | Kombination von bisphosphonat und tetracyclin | |
BR0010562A (pt) | Inibidor de metaloprotease do ácido hidrox mico de sulfona aromática | |
DE602005022826D1 (de) | Kontrolle der Androgen Rezeptor-abhängigen Gen Expression durch Hemmung der Aminoxidase Aktivität der Lysin spezifischen Demethylase (LSD1) | |
BR9813222A (pt) | Agente e alimento funcional antitensão | |
BR0312768A (pt) | Compostos de 5-ariltetrazol, composições do mesmo e usos dos mesmos | |
DE60026279D1 (de) | Zusammenstellungen zur prophylaxe und behandlung von allergien des typus i | |
BR0112770A (pt) | Agentes herbicidas | |
BR0211430A (pt) | Compostos ou seus sais, processos para prevenção ou tratamento de condições, processo para prevenção ou tratamento de uma doença e usos de compostos | |
BRPI0508333A (pt) | uso de um composto de vitamina d, método de prevenir e/ou tratar cistite intersticial, formulação farmacêutica, composto de vitamina d, e, kit | |
BR0009280A (pt) | Composições antimicrobianas para limpeza dedentaduras | |
BR0316133A (pt) | ácidos hidroxâmicos de sulfona aromática e seu uso como inibidores de protease | |
BR9910678A (pt) | Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto | |
BR9814214A (pt) | Composição com ácido azeláico | |
BR0316163A (pt) | Inibidores de histona desacetilase para tratamento de doenças degenerativas do olho | |
ATE368447T1 (de) | Verwendung eines assoziates aus synergistischen kalziumkanalblocker-agentien zur vermeidung oder behandlung von falten und feinen linien | |
BR0317947A (pt) | Inibidores de quinurenina 3-hidroxilase para o tratamento de diabetes | |
BR0215336A (pt) | Utilização de um composto ou um sal farmaceuticamente aceitável do mesmo, composto, e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2029 DE 24/11/2009. |